ECTRIMS eLearning

Gait pattern in patients with different multiple sclerosis phenotypes
Author(s): ,
I.P Dujmovic Basuroski
Affiliations:
Department of Neurology, University of Belgrade School of Medicine;Clinic of Neurology, Clinical Centre of Serbia
,
S Radovanovic
Affiliations:
Institute for Medical Research, University of Belgrade
,
V Martinovic
Affiliations:
University of Belgrade School of Medicine
,
J Dackovic
Affiliations:
Clinic of Neurology, Clinical Centre of Serbia
,
G Maric
Affiliations:
Institute for Epidemiology, University of Belgrade School of Medicine, Belgrade, Serbia
,
S Mesaros
Affiliations:
Department of Neurology, University of Belgrade School of Medicine;Clinic of Neurology, Clinical Centre of Serbia
,
T Pekmezovic
Affiliations:
Institute for Epidemiology, University of Belgrade School of Medicine, Belgrade, Serbia
J Drulovic
Affiliations:
Department of Neurology, University of Belgrade School of Medicine;Clinic of Neurology, Clinical Centre of Serbia
ECTRIMS Learn. Dujmovic Basuroski I. 09/16/16; 145783; P1099
Irena P. Dujmovic Basuroski
Irena P. Dujmovic Basuroski
Contributions
Abstract

Abstract: P1099

Type: Poster

Abstract Category: Pathology and pathogenesis of MS - Neurophysiology

Background: Gait pattern was reported to be impaired in multiple sclerosis (MS) patients even at the early disease stages, but gait pattern characteristics in patients with different MS phenotypes have not been fully elucidated.

Aim: We analyzed spatio-temporal gait pattern characteristics in MS patients with relapsing-remitting (RR) and primary-progressive (PP) MS in comparison with healthy controls (Co).

Patients and methods: The study comprised 70 (52 RR, 18 PP) MS patients (29 male, 41 female; mean age±SD, 37.2±10.5 years; median disease duration 5.3 years) and 40 sex- and age-matched healthy Co. In MS patients, neurological disability was assessed using the Expanded Disability Status Scale (EDSS). Median EDSS score in RRMS and PPMS patients was 3.0 (range, 0-5.0) and 4.5 (range, 3.0-6.0), respectively. Gait pattern measurements were performed using a GAITRite electronic walkway of 5.5 m active area. All subjects performed a standardized self-paced basic, simple walking task (task A), a dual-motor task (task A+ task B: holding a glass fully filled with water, aiming not to spill the water), a dual-motor/mental task (task A+ task C: serial "7" subtraction), and a triple combined motor/mental task (task A+ task B+ task C). Analyzed spatio-temporal gait parameters were: cycle time (CT), stride length (SL), swing time (ST) and double support time (DST).

Results: With each task performed, CT and DST in the total MS group were significantly longer and SL significantly shorter than in Co while ST was similar in the total MS patient group and Co. Patients with PPMS had significantly longer CT and DST and significantly shorter SL than both RRMS and Co at each of the tasks. At the dual motor task, ST was significantly longer in PPMS than in RRMS or Co while ST was similar in RRMS and PPMS at all other measurements. EDSS score correlated significantly with CT, DST and SL but no significant correlation was found with ST. In the total MS group, the simple walking paradigm and the triple motor/mental paradigm differed significantly in all studied gait parameters.

Conclusion: Patients with RRMS and PPMS differ in gait pattern characteristics, reflecting the differences in their functional capacity. Additionally, differences in gait pattern between MS patients and healthy people might partly contribute to the increased risk of falling in the MS population.

Disclosure: I. Dujmovic Basuroski received lecture fees and/or travel grants from Merck Serono,

Bayer, Medis, Teva and Boehringer Ingelheim and The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175031).

S. Radovanovic received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175090).

V. Martinovic received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175087).

J. Dackovic received travel honoraria from Teva.

G. Maric received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175087).

S. Mesaros received speaker`s honoraria from Merck and Novartis; travel expenses from Bayer, Merck, Genzyme, Medis, and Teva and The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175031).

T. Pekmezovic received honoraria for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, and Actavis and The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175087).

J. Drulovic received honoraria for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, Medis, and Actavis; The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175031).

Abstract: P1099

Type: Poster

Abstract Category: Pathology and pathogenesis of MS - Neurophysiology

Background: Gait pattern was reported to be impaired in multiple sclerosis (MS) patients even at the early disease stages, but gait pattern characteristics in patients with different MS phenotypes have not been fully elucidated.

Aim: We analyzed spatio-temporal gait pattern characteristics in MS patients with relapsing-remitting (RR) and primary-progressive (PP) MS in comparison with healthy controls (Co).

Patients and methods: The study comprised 70 (52 RR, 18 PP) MS patients (29 male, 41 female; mean age±SD, 37.2±10.5 years; median disease duration 5.3 years) and 40 sex- and age-matched healthy Co. In MS patients, neurological disability was assessed using the Expanded Disability Status Scale (EDSS). Median EDSS score in RRMS and PPMS patients was 3.0 (range, 0-5.0) and 4.5 (range, 3.0-6.0), respectively. Gait pattern measurements were performed using a GAITRite electronic walkway of 5.5 m active area. All subjects performed a standardized self-paced basic, simple walking task (task A), a dual-motor task (task A+ task B: holding a glass fully filled with water, aiming not to spill the water), a dual-motor/mental task (task A+ task C: serial "7" subtraction), and a triple combined motor/mental task (task A+ task B+ task C). Analyzed spatio-temporal gait parameters were: cycle time (CT), stride length (SL), swing time (ST) and double support time (DST).

Results: With each task performed, CT and DST in the total MS group were significantly longer and SL significantly shorter than in Co while ST was similar in the total MS patient group and Co. Patients with PPMS had significantly longer CT and DST and significantly shorter SL than both RRMS and Co at each of the tasks. At the dual motor task, ST was significantly longer in PPMS than in RRMS or Co while ST was similar in RRMS and PPMS at all other measurements. EDSS score correlated significantly with CT, DST and SL but no significant correlation was found with ST. In the total MS group, the simple walking paradigm and the triple motor/mental paradigm differed significantly in all studied gait parameters.

Conclusion: Patients with RRMS and PPMS differ in gait pattern characteristics, reflecting the differences in their functional capacity. Additionally, differences in gait pattern between MS patients and healthy people might partly contribute to the increased risk of falling in the MS population.

Disclosure: I. Dujmovic Basuroski received lecture fees and/or travel grants from Merck Serono,

Bayer, Medis, Teva and Boehringer Ingelheim and The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175031).

S. Radovanovic received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175090).

V. Martinovic received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175087).

J. Dackovic received travel honoraria from Teva.

G. Maric received The Ministry of Education, Science and Technological Development of the Republic of Serbia grant support (No. 175087).

S. Mesaros received speaker`s honoraria from Merck and Novartis; travel expenses from Bayer, Merck, Genzyme, Medis, and Teva and The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175031).

T. Pekmezovic received honoraria for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, and Actavis and The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175087).

J. Drulovic received honoraria for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, Medis, and Actavis; The Ministry of Education, Science and Technological Development, Republic of Serbia grant support (No. 175031).

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies